Tvardi Therapeutics, Inc. (TVRD)
NASDAQ: TVRD · Real-Time Price · USD
2.510
-0.050 (-1.95%)
Jul 24, 2026, 4:00 PM EDT - Market closed
Tvardi Therapeutics Stock Forecast
Stock Price Forecast
According to 9 analysts polled by S&P Global, Tvardi Therapeutics stock has a consensus rating of "Buy" and an average price target of $9.75. The average 1-year stock price forecast is 288.45% higher than the current stock price, while the lowest is $3.00 (+19.52%) and the highest is $15 (+497.61%).
Price Target: $9.75 (+288.45%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Tvardi Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 5 | 5 |
| Buy | 0 | 0 | 0 | 0 | 0 | 2 |
| Hold | 4 | 4 | 3 | 3 | 3 | 1 |
| Sell | 0 | 0 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Upgrades $13 | Buy | Upgrades | $13 | +417.93% | Jul 8, 2026 |
| BTIG | BTIG | Buy Maintains $15 | Buy | Maintains | $15 | +497.61% | Jul 8, 2026 |
| Raymond James | Raymond James | Buy Upgrades $10 | Buy | Upgrades | $10 | +298.41% | Jul 8, 2026 |
| Barclays | Barclays | Sell Maintains $3 | Sell | Maintains | $3 | +19.52% | Jul 8, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Maintains $9 | Buy | Maintains | $9 | +258.57% | Jul 7, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.34
from -2.46
EPS Next Year
-2.73
from -2.34
EPS and Forward PE are based on non-GAAP adjusted numbers.